Cognition Therapeutics (NASDAQ:CGTX) Rating Increased to Strong-Buy at Brookline Capital Management

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by equities research analysts at Brookline Capital Management to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Other analysts have also recently issued research reports about the stock. Chardan Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of Cognition Therapeutics in a research note on Thursday, December 19th. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. Finally, HC Wainwright lifted their price objective on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $8.30.

Cognition Therapeutics Stock Performance

NASDAQ:CGTX opened at $0.76 on Monday. The stock has a market capitalization of $31.53 million, a price-to-earnings ratio of -0.78 and a beta of 0.95. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95. The stock has a fifty day moving average price of $0.60 and a two-hundred day moving average price of $0.70.

Institutional Investors Weigh In On Cognition Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CGTX. Virtu Financial LLC acquired a new position in shares of Cognition Therapeutics during the 3rd quarter valued at $27,000. Mercer Global Advisors Inc. ADV boosted its position in shares of Cognition Therapeutics by 33.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after buying an additional 24,050 shares during the period. Sigma Planning Corp lifted its position in Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after acquiring an additional 25,050 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Cognition Therapeutics in the 4th quarter worth approximately $26,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.